Theme: Scientific Novelty and Advanced Perception in Medicinal Chemistry

MedChem & MTDD 2018
scientific program

Renowned Speakers

MedChem & MTDD 2018

Details of Medchem and MTDD Conference 2018 in USA:

 

Conference Name

 

Place

 

Date

   Medchem&MTDD 2018

 

San Francisco, California, USA.

November 05-06 , 2018

 


Conference Series LLC Ltd welcome professional chemists, researchers, professors, scientific communities, delegates, students, business professionals and executives from all over the world to attend the 19th International Conference on Medicinal Chemistry and Multi-Targeted Drug Delivery scheduled during November 05-06, 2018 in San Francisco, USA

Medicinal chemistry explores different ways how chemists are modifying molecules structure so as to design innocuous and effective drugs. It is one of the most rapidly developing areas within chemistry, both globally and locally.The different spectroscopic techniques for drug design, synthesis and characterization of novel therapeutic agents including small molecules, peptide drugs and natural products will be discussed. Applications in novel methods of drug delivery systems and formulations for better bioavailability of bioactive compounds are also welcomed

 Medchem And MTDD  will likewise give the fantastic chance to meet specialists, trade data, and reinforce the coordinated effort among Directors, Researchers, Associate Professors, and Scholars from both scholarly community and industry.

Medchem And MTDD  will cover all areas of Medicinal chemistry

Conference Highlights are:

·          Medicinal Chemistry and Drug Discovery

·          Principles of Medicinal Chemistry

·          Medicinal Chemistry Aspects of Drug Action and Drug Metabolism

·          Drug Metabolism

·          Molecular Biology - A New Route to Drug Discovery

·          Fusion of Traditional And Biomedicine

·          Plant Genomics

·          Pharmaceuticals Vs Nutraceuticals

·          Frontiers In Chemistry

·          Computer Aided Drug Designing

·          Drug Chemistry

·          Hyphenated Chromatographic Techniques

·          Cancer Studies: Drug Delivery Chemistry

·          Neuro Degenerative Disease

·          Vaccines And Autism

·          Emerging Infectious Diseases

Target Audience:

·          Eminent Scientific Professionals in Pharma and Chemistry

·          Faculty (Professors, Associate Professors, Asst. Professors )

·          Pharma and Chemistry Colleges & Training Institutes

·          Pharmaceutical  and Chemistry Associations and Societies

·          Pharmaceutical Business Entrepreneurs

·          Manufacturing Pharmaceutical products Companies

·          Manufacturing Medical Devices Companies

·          Pharma and Chemistry Students

·          PhD Scholars, Graduates and Post Graduates

·          Directors, CEO’s of Organizations

·          Association, Association presidents and professionals

·          Noble laureates in Health Care and Medicine

·          Bio instruments Professionals

·          Bio-informatics Professionals

·          CRO and DATA management Companies

·          Data Management Companies

Conference Series LLC Ltd  organises 800+ Conferences every year across USA, Europe & Asia with support from 1000 more scientific societies and publishes 400+ Open access journals which contains over 50000 eminent personalities, reputed scientists as editorial board members.

For abstract submission please click: https://medicinalchemistry.pharmaceuticalconferences.com/abstract-submission.php

We are eagerly waiting to meet you at San Francisco, California for the MedChem & MTDD 2018 Meeting

Track 1 Medicinal Chemistry and Drug Discovery

 

Track 2: Structure-based drug design, virtual screening

 

          Track 3: Medicinal Chemistry Aspects of Drug Action and Drug Metabolism

Track 4: Drug Metabolism

Track 5: Molecular Biology - A New Route to Drug Discovery

Track 6 Fusion of Traditional And Biomedicine

Track 7  Plant Genomics

Track 8   Pharmaceuticals Vs Nutraceuticals

Track 9 Frontiers In Chemistry

Track 10 Computer Aided Drug Designing

Track 11 Targeted Drug Delivery System-TDDS (Smart Drug Delivery)

Track 12 Drug Chemistry

Track 13 Hyphenated Chromatographic Techniques

Track 14 Cancer Studies: Drug Delivery Chemistry

Track 15  Neuro Degenerative Disease

Track 16 Vaccines And Autism

Track 17 Emerging Infectious Diseases

Track 18 Antibiotics

Track 19 Personalised Medicines And Drugs

Track 20 Medchem-Antimicrobial And Infectious Agents

Track 21 Chem Virology (zika virus)

    Track 22 New Trends In Pharmacology And Drug Development

Track 23 Novel Drug Discovery And Drug Delivery

Track 24 Chemical Biology

Track 25  Novel Research: Hit To Lead

      Track 26: Advanced Medicinal Chemistry

Track 27: Scientific Drug Discovery Breakthroughs For Deadly Diseases

Track 28: Fluorine in Medicinal Chemistry: Recent Therapeutic Applications of Fluorinated Small Molecules

Track 29: Human Cytochrome P-450 Biochemistry

Track 30: Immunizing and Antimicrobial Agents

Track 31: Biophysical Enzymology and Biopharmaceuticals 

Track 32: Integrated Pharmacology

Track 33: Diagnostic Medicinal Chemistry

Track 34: Anticancer and Anti-Diabetic Agents

Track 35: Immunotherapy-Oncology

Track 36: Sources of leads

Track 37: Drug Biotransformation and Disposition

Track 38: Epigenetic gene silencing in cancer

Track 39: Nanotechnology in Drug Delivery Systems

Track 40: Pharmacology

Track 41: Medical Devices for Drug Delivery

Track 42: Survey of Therapeutics 

 

Market: Opportunities and Competitive Dynamics

It has been estimated that in the field of Medicinal chemistry more than $79 million has spent in research funding since 2008. A complete overview of drug designing process with comparison to conventional approaches of drug discovery has come up with some crucial details, which says that from year 2008 to 2013 the market has grown to $198 billion and in further this rate may increases to $236 Billion from year 2014 to 2019. Special emphasis has given on computational approaches for drug discovery along with salient features and applications of the software’s used in novel research studies.

The hugest test in this industry is to reduce the quantity of medications that bomb in pre-clinical stages, as this encourages the maker to enter the market with a profligate medication. Be that as it may, since the ADME profiling utilized as a part of silico and cell approaches have effectively lessened the weakening rate. As per industry specialists as of now structure-based medication configuration has high acknowledgment took after by part based variety, common items, while decent variety situated blend and chemo genomics have unimportant pieces of the overall industry. The best five dynamic restorative research regions are tumour, contaminations, neurological, gastrointestinal, endocrine and cardiovascular.

Medication revelation is relied upon to be to a great extent polished at little specialty biopharmaceutical organizations around the globe in the U.K., U.S., Western Europe, Eastern Europe, China, India, Brazil, South Africa and Mexico as speculations, time and dangers are similarly less in this operations demonstrate than the customary. Generally speaking the restorative science has enhanced every one of these years with all refreshed advances and procedures.

The significance of little and medium scaled organizations will increment in this market as it will diminish the time and cost for a major pharmaceutical organization. Subsequently, in tranquilize disclosure therapeutic science assumes imperative part yet at the same time the exactness and accuracy of the examination should be enhanced to accomplish least dismissals in the preclinical investigations.

The report offers a far reaching assessment of the market. It does as such by means of top to bottom subjective bits of knowledge, authentic information, and certain projections about market estimate. The projections included in the report have been inferred utilizing demonstrated research strategies and presumptions. Thusly, the exploration report fills in as a store of examination and data for each aspect of the market, including however not constrained to: Regional markets, innovation, sorts, and applications. 

Importance & Scope

Significance of recent trends reviews the state of the art and aims to determine the significance of technology and market trends in medicinal chemistry for advancing productivity in drug discovery. One in particular, fragment-based drug design, stands out as promising major improvements in research productivity. After analysis it proves that medicinal chemistry-related approaches and methodologies that drug discovery organizations employ in an effort to increase productivity in early drug discovery. Its key topics considered include structure-based drug design, fragment-based drug design, natural products-based drug design, diversity-oriented synthesis, and chemogenomics. Various ways of computer-aided drug design are also considered, as the complexity and limitations of drug discovery programs that are based on biochemical screens of large compound collections have been major factors in stimulating the growth of this modality.

Why San Francisco, USA?

San Francisco has been a major hub for pharmaceutical companies. It has maintained a stout lead over drug makers in our annual ranking of the largest Bio-Pharma companies in USA.

However, the pharmaceutical market is still dominated by a few very large companies that control the import/distribution, retail and manufacturing sectors.

Conference Highlights

  • Medicinal Chemistry and Drug Discovery
  •  Principles of Medicinal Chemistry
  • Medicinal Chemistry Aspects of Drug Action and Drug Metabolism
  • Drug Metabolism
  •  Molecular Biology - A New Route to Drug Discovery
  • Fusion of Traditional And Biomedicine
  •  Plant Genomics
  • Pharmaceuticals Vs Nutraceuticals
  • Frontiers In Chemistry
  • Computer Aided Drug Designing
  • Drug Chemistry
  • Hyphenated Chromatographic Techniques
  • Cancer Studies: Drug Delivery Chemistry
  •  Neuro Degenerative Disease

A Unique Opportunity for Advertisers and Sponsors at this International event:

https://medicinalchemistry.pharmaceuticalconferences.com/sponsors.php

Major Marketing Associations around the Globe

  • American Association for Clinical Chemistry
  •  American Chemical Society
  •   American Institute of Chemists (AIC)
  • American Society of Brewing Chemists
  • American Society for Mass Spectrometry
  •   Royal Society of Chemistry (RSC)
  •  Swedish Chemical Society
  • New Swiss Chemical Society
  •  Syngenta, Hyderabad Area, India
  •  DCTG, Beijing City, China
  •    Oceanus Group Ltd, Singapore
     

Major Marketing Associations in USA

  •  American Association for Clinical Chemistry
  • American Chemical Society
  •  American Institute of Chemists(AIC)
  • American Society of Brewing Chemists
  • American Society for Mass Spectrometry

Why to attend???

Meet your target market with members from around the world focused on learning about advertising and marketing, this is your single best opportunity to reach the largest assemblage of participants from all over the world. Conduct demonstrations, distribute information, meet with current and potential customers, make a splash with a new product line, and receive name recognition at this 3-day event. World-renowned speakers, the most recent techniques, tactics, and the newest updates in advertising and marketing fields are hallmarks of this conference

USA Pharmaceutical Companies Associated with Advertising and Marketing Activities

The United States is the largest market for pharmaceuticals (including biopharmaceuticals), accounting for around 35 percent of the global market, and is the world leader in biopharmaceutical research and development (R&D). According to the Pharmaceutical Research and Manufacturers Association (PhRMA), U.S. firms conduct the majority of the world's research and development in pharmaceuticals and hold the intellectual property rights on most new medicines. The biopharmaceutical pipeline also has over 7,000 new medicines currently in development around the world with approximately 3,500 compounds currently being studied in the United States - more than any other region around the world. The National Science Foundation reports that the U.S. biopharmaceutical sector accounts for the largest single share of all U.S. business research and development (R&D) investment, representing 23.4 percent of all domestic R&D funded by U.S. business in 2013.

More than 854,000 people work in the biopharmaceutical industry in the United States across a broad range of occupations, such as scientific research, technical support and manufacturing. Directly and indirectly, the industry supports a total of 4.4 million jobs across the United States and added an estimated $1.2 trillion in economic output in 2014, representing 3.8 percent of total U.S. output. The biopharmaceutical industry provides average salaries well above the average for all U.S. workers, and requires a highly-skilled and educated workforce from the administrative level up to and including Ph.D. scientists.  

Fast growing segments of the pharmaceutical market include biologics, generics and over-the-counter (OTC) drugs. Biologics now account for over a third of all new drugs in clinical trials or awaiting FDA approval. U.S. generic drug sales reached an estimated $70 billion in 2015, representing a quarter of the global market, due to a large number of drugs going off-patent and healthcare reforms favouring generics.  OTC market growth will be driven by a growing aging population, consumer trends towards self-medication, and the conversion of drugs from prescription to non-prescription or OTC status.

The United States has one of the world’s most supportive domestic environments for the development and commercialization of pharmaceuticals with minimal market barriers. Its strengths include an intellectual property system that rewards innovation through patent and data protection, a science-based regulatory system that is considered the most rigorous in the world, the world’s largest scientific research base fostered by academic institutions and decades of government research funding, and robust capital markets. enterprises.

In addition, the United States is the world’s largest free-pricing market for pharmaceuticals and has high per capita incomes, a large elderly population, and high rates of chronic diseases and drug consumption. All of these factors ensure that the United States will remain the world’s most important pharmaceutical market for the foreseeable future with healthy growth expected across all product sectors.

Figure 1: Associations and Societies Dealing with Medicinal Chemistry

       

Figure 2: Companies dealing with Medicinal Chemistry and Drug Delivery

   

It has been estimated that in the field of Medicinal chemistry more than $79 million has spent in research funding since 2008. The Market report of most of the pharmaceutical companies shows their R&D investments majorly in the following areas, namely:

  • Advanced Drug Delivery Systems

  • Antibiotics

  • Excipients in Pharmaceuticals

  • Ophthalmic Therapeutic Drugs

  • Skin Disease Treatment

  • Vaccine Technologies

  • Breakthrough Therapies

Advanced Drug Delivery Systems:

  • The global advanced drug delivery market should grow from roughly $178.8 billion in 2015 to nearly $227.3 billion by 2020, with a compound annual growth rate (CAGR) of 4.9%.

  • The North American market should grow from nearly $75.7 billion in 2015 to $93.4 billion by 2020, a CAGR of 4.3%.

  • The European market should grow from roughly $57.3 billion in 2015 to nearly $72.1 billion by 2020, a CAGR of 4.7%.

  • 4.7%.

Figure 3: Global Advanced Drug Delivery Market 

2017  Review

Pharmaceuticals represented a US$300 bn-a-year market globally as of 2015, the World Health Organization states. The global pharmaceutical market is expected to surpass US$400 bn by 2018, with the ten largest pharmaceutical companies collectively commanding about a third of the market. Companies in the pharmaceutical industry are characterized by their sizeable expenditure on R&D and marketing initiatives in a bid to rake in more revenue. The development of biopharmaceuticals represents a milestone for the industry and personalized therapies carry immense promise in the near future.

Highlights

  • The global market for cancer vaccines totaled $4.5 billion in 2013 and reached nearly $4.0 billion in 2014. This market is expected to reach $4.3 billion by 2019, registering a compound annual growth rate (CAGR) of 1.3% for the period 2014-2019.
  • The global market for “silent” cancers was valued at $8.5 billion in 2013 and $9 billion in 2014. This market is expected to reach almost $13.6 billion by 2019, with a CAGR of 8.5% from 2014 to 2019.
  • The global market for incretin-based therapeutics was valued at nearly $11.8 billion in 2013 and $12.7 billion in 2014. This market is expected to reach $22.8 billion by 2019, with a CAGR of 12.4% from 2014 to 2019.

Cancer Vaccines: Technologies and Global Markets

The global human vaccines market was valued at US$28.3 bn in 2015 and is estimated to reach US$72.5 bn by 2024, registering an 11.2% CAGR during the forecast period. Extensive promotion and marketing strategies and favourable government support are likely to boost market growth.

The global market for cancer vaccines was valued at nearly $4.2 billion and $4.0 billion in 2014 and 2015, respectively. This market is expected to decline from nearly $3.5 billion in 2016 to $3.4 billion in 2021 at a compound annual growth rate (CAGR) of -0.4% for 2016-2021.

Drug Delivery Companies:

The global drug delivery technology market is projected to reach USD 1,669.40 Billion by 2021 from USD 1,179.20 Billion in 2016, at a CAGR of 7.2% during the forecast period. This market is segmented based on route of administration, facility of use, and region.

The drug delivery technology is highly competitive market, comprising of various players. Prominent players in the drug delivery technology market include Johnson & Johnson, Inc. (U.S.), F. Hoffman-La Roche (Switzerland), Merck & Co., Inc. (U.S.), Bayer AG (Germany), Pfizer, Inc. (U.S.), Novartis AG (Switzerland), 3M Company (U.S.), Becton, Dickinson and Company (U.S.), GlaxoSmithKline plc, (U.K.), Sanofi (France), and Antares Pharma, Inc. (U.S.).

Nanotechnology Drug Delivery Market

The global nanotechnology drug delivery market was valued at US$ 41,062.5 Mn in 2014 and is projected to reach US$ 118,527.2 Mn by 2023, expanding at a CAGR of 12.5% from 2015 to 2023.

Key players having presence in the global nanotechnology drug delivery market are AbbVie, Inc., Amgen, Inc., Celgene Corporation, Johnson & Johnson, Merck & Co., Inc., and Novartis International AG, among others.

Target Audience

  • Drug Delivery Technology Manufacturers
  • Public and Private Physicians
  • Healthcare Institutions (Medical Data Centers)
  • Research & Clinical Laboratories
  • Distributors and Suppliers of Drug Delivery Technologies
  • Health Insurance Payers
  • Market Research and Consulting Firms

 

 

Conference Highlights

To share your views and research, please click here to register for the Conference.

To Collaborate Scientific Professionals around the World

Conference Date November 05-06, 2018
Sponsors & Exhibitors Click here for Sponsorship Opportunities
Speaker Opportunity Closed
Poster Opportunity Closed Click Here to View

Media Partners